GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 206 filers reported holding GENMAB A/S in Q2 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,859 | +15.2% | 478 | +24.2% | 0.00% | +50.0% |
| Q2 2023 | $14,634 | +10.1% | 385 | +9.4% | 0.00% | 0.0% |
| Q1 2023 | $13,292 | -29.0% | 352 | -20.4% | 0.00% | -33.3% |
| Q4 2022 | $18,732 | +87.3% | 442 | +42.1% | 0.00% | +50.0% |
| Q3 2022 | $10,000 | +150.0% | 311 | +150.8% | 0.00% | +100.0% |
| Q2 2022 | $4,000 | -50.0% | 124 | -43.9% | 0.00% | 0.0% |
| Q1 2022 | $8,000 | 0.0% | 221 | +4.2% | 0.00% | 0.0% |
| Q4 2021 | $8,000 | +60.0% | 212 | +73.8% | 0.00% | 0.0% |
| Q3 2021 | $5,000 | +25.0% | 122 | +22.0% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | +300.0% | 100 | +203.0% | 0.00% | – |
| Q1 2021 | $1,000 | -91.7% | 33 | -88.2% | 0.00% | -100.0% |
| Q4 2020 | $12,000 | +500.0% | 280 | +522.2% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | +100.0% | 45 | +150.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 18 | +50.0% | 0.00% | – |
| Q1 2020 | $0 | – | 12 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 52,148 | $1,839,260 | 1.67% |
| Ativo Capital Management LLC | 28,442 | $1,003,132 | 1.13% |
| HARDING LOEVNER LP | 3,204,230 | $113,013,183 | 0.75% |
| Hardman Johnston Global Advisors LLC | 592,318 | $20,891,056 | 0.70% |
| Yorktown Management & Research Co Inc | 16,600 | $585,482 | 0.66% |
| TORRAY INVESTMENT PARTNERS LLC | 104,516 | $3,686,279 | 0.65% |
| First Light Asset Management, LLC | 157,147 | $5,542,575 | 0.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,300 | $1,561,575 | 0.53% |
| Capricorn Fund Managers Ltd | 37,007 | $1,305,237 | 0.45% |
| Legacy Wealth Asset Management, LLC | 29,496 | $1,040,324 | 0.38% |